Effects of Vitamin K2 on the Development of Osteopenia in Rats as the Models of Osteoporosis.
10.3349/ymj.2006.47.2.157
- Author:
Jun IWAMOTO
1
;
Tsuyoshi TAKEDA
;
Yoshihiro SATO
Author Information
1. Department of Sports Medicine, Keio University School of Medicine, Tokyo, Japan. jiwamoto@sc.itc.keio.ac.jp
- Publication Type:Review
- Keywords:
Vitamin K2;
bone formation;
bone resorption;
rat;
osteopenia
- MeSH:
Vitamin K 2/chemistry/metabolism/*pharmacology;
Tomography, X-Ray Computed;
Tibia/pathology;
Rats;
Osteoporosis/*drug therapy/*prevention & control;
Male;
Magnesium Deficiency/diagnosis;
Magnesium/metabolism;
Homeostasis;
Female;
*Disease Models, Animal;
Diphosphonates;
Calcium/metabolism;
Bone and Bones/*drug effects/metabolism;
Bone Resorption;
Bone Diseases, Metabolic/*metabolism;
Animals
- From:Yonsei Medical Journal
2006;47(2):157-166
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vitamin K2 is widely used for the treatment of osteoporosis in Japan. To understand the effects of vitamin K2 on bone mass and bone metabolism, we reviewed its effects on the development of osteopenia in rats, which characterizes models of osteoporosis. Vitamin K2 was found to attenuate the increase in bone resorption and/or maintain bone formation, reduce bone loss, protect against the loss of trabecular bone mass and its connectivity, and prevent the decrease in strength of the long bone in ovariectomized rats. However, combined treatment of bisphosphonates and vitamin K2 had an additive effect in preventing the deterioration of the trabecular bone architecture in ovariectomized rats, while the combined treatment of raloxifene and vitamin K2 improved the bone strength of the femoral neck. The use of vitamin K2 alone suppressed the increase in trabecular bone turnover and endocortical bone resorption, which attenuated the development of cancellous and cortical osteopenia in orchidectomized rats. In addition, vitamin K2 inhibited the decrease in bone formation in prednisolone-treated rats, thereby preventing cancellous and cortical osteopenia. In sciatic neurectomized rats, vitamin K2 suppressed endocortical bone resorption and stimulated bone formation, delaying the reduction of the trabecular thickness and retarding the development of cortical osteopenia. Vitamin K2 also prevented the acceleration of bone resorption and the reduction in bone formation in tail-suspended rats, which counteracted cancellous bone loss. Concomitant use of vitamin K2 with a bisphosphonate ameliorated the suppression of bone formation and more effectively prevented cancellous bone loss in tail-suspended rats. Vitamin K2 stimulated renal calcium reabsorption, retarded the increase in serum parathyroid hormone levels, and attenuated cortical bone loss primarily by suppressing bone resorption in calcium-deficient rats while maintaining the strength of the long bone in rats with magnesium deficiency. These findings suggest that vitamin K2 may not only stimulate bone formation, but may also suppress bone resorption. Thus, vitamin K2 could regulate bone metabolism in rats, which represented the various models of osteoporosis. However, the effects of vitamin K2 on bone mass and bone metabolism seem to be modest.
